Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million

Wall Street analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to report $1.68 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Assembly Biosciences’ earnings. The lowest sales estimate is $700,000.00 and the highest is $2.66 million. The firm is expected to report its next earnings results on Thursday, March 1st.

According to Zacks, analysts expect that Assembly Biosciences will report full year sales of $1.68 million for the current year, with estimates ranging from $4.40 million to $8.36 million. For the next year, analysts forecast that the firm will report sales of $3.82 million per share, with estimates ranging from $2.80 million to $4.83 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Assembly Biosciences.

Several research firms have recently issued reports on ASMB. BidaskClub raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. ValuEngine raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 3rd. Zacks Investment Research cut Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. B. Riley began coverage on Assembly Biosciences in a research report on Friday, January 5th. They set a “neutral” rating and a $35.00 price objective for the company. Finally, Jefferies Group began coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They set a “buy” rating and a $50.00 price objective for the company. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $39.25.

Assembly Biosciences (NASDAQ ASMB) opened at $42.85 on Monday. Assembly Biosciences has a 1 year low of $18.60 and a 1 year high of $52.37.

In related news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $49.37, for a total value of $49,370.00. Following the completion of the sale, the director now directly owns 20,465 shares of the company’s stock, valued at approximately $1,010,357.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 3,000 shares of company stock valued at $141,270. Insiders own 19.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jennison Associates LLC boosted its position in shares of Assembly Biosciences by 19.6% in the 4th quarter. Jennison Associates LLC now owns 2,120,300 shares of the biopharmaceutical company’s stock valued at $95,944,000 after purchasing an additional 347,025 shares during the period. BlackRock Inc. boosted its position in shares of Assembly Biosciences by 19.6% in the 4th quarter. BlackRock Inc. now owns 1,078,097 shares of the biopharmaceutical company’s stock valued at $48,784,000 after purchasing an additional 176,976 shares during the period. Vanguard Group Inc. boosted its position in shares of Assembly Biosciences by 21.2% in the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock valued at $12,615,000 after purchasing an additional 107,065 shares during the period. State Street Corp acquired a new stake in shares of Assembly Biosciences in the 2nd quarter valued at about $4,234,000. Finally, Northern Trust Corp boosted its position in shares of Assembly Biosciences by 221.2% in the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock valued at $4,033,000 after purchasing an additional 134,513 shares during the period. 65.04% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/12/brokerages-anticipate-assembly-biosciences-inc-asmb-will-announce-quarterly-sales-of-1-68-million.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply